Cellectis S.A.
biopharmaceutical company
CLLS Nasdaq
SEC CIK 1627281
Follow Cellectis S.A.
Weekly email: filings, results, news
EPS, diluted
-
Source: SEC XBRL filings · latest filing
- Revenue
- Net income
Show the numbers
| Year | Revenue | Net income |
|---|---|---|
| FY25 | $72.9M | −$67.6M |
| FY24 | $41.5M | −$36.8M |
| FY23 | $755K | −$101.1M |
| FY22 | $19.2M | −$106.1M |
| FY21 | $30.3M | −$114.2M |
| FY20 | $51.1M | −$81.1M |
| FY19 | $15.2M | −$102.1M |
| FY18 | $12.7M | −$78.7M |
| FY17 | $25.2M | −$99.4M |
| FY16 | $44.8M | −$67.3M |
| FY15 | $55.9M | −$22.8M |
| FY14 | - | −$1.3M |
- Gross margin
- Operating margin
- Net margin
Show the numbers
| Year | Gross margin | Operating margin | Net margin |
|---|---|---|---|
| FY25 | 100% | −45.3% | −92.7% |
| FY24 | 100% | −143.5% | −88.6% |
| FY23 | 2.4% | −12887.7% | −13385.3% |
| FY22 | 90.8% | −467.7% | −553.6% |
| FY21 | 93.9% | −341% | −376.3% |
| FY20 | 96.2% | −82.9% | −158.8% |
| FY19 | 25% | −813.4% | −672.1% |
| FY18 | 78.5% | −825.5% | −618.1% |
| FY17 | 89.6% | −367.8% | −394.5% |
| FY16 | - | −150.2% | −150.1% |
| FY15 | - | −55.5% | −40.8% |
| FY14 | - | - | - |
Show the numbers
| Year | Free cash flow |
|---|---|
| FY25 | −$41.8M |
| FY24 | $20.4M |
| FY23 | −$25.8M |
| FY22 | −$89.9M |
| FY21 | −$123.1M |
| FY20 | −$124.3M |
| FY19 | −$82.1M |
| FY18 | −$72.9M |
| FY17 | −$54.7M |
| FY16 | −$46.4M |
| FY15 | −$725K |
| FY14 | - |
- Cellectis S.A.
- Healthcare median
Show the numbers
| Year | Cellectis S.A. | Healthcare median |
|---|---|---|
| FY25 | −92.7% | −40.6% |
| FY24 | −88.6% | −60.7% |
| FY23 | −13385.3% | −97.1% |
| FY22 | −553.6% | −128.5% |
| FY21 | −376.3% | −129.2% |
| FY20 | −158.8% | −136.5% |
| FY19 | −672.1% | −133.7% |
| FY18 | −618.1% | −173.4% |
| FY17 | −394.5% | −176.7% |
| FY16 | −150.1% | −164.8% |
| FY15 | −40.8% | −183.4% |
| FY14 | - | −133% |
News
No stories filed under Cellectis S.A. yet - coverage appears here as the news feed clusters it.